C91.0
Conditions
Interventions
Group 1: Prospective data acquisition of diagnosis, treatment and course of disease in adult acute lymphoblastic leukemia (ALL) and related diseases in conjunction with a prospective collection of
Sponsors
GMALL-Studiengruppe
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: # Age min . 18 years # Written informed consent # Therapy analogous to a GMALL therapy optimization study or GMALL therapy recommendation # One of the following three inclusion criteria : # 1 acute lymphoblastic leukemia # 2 other leukemias (NK-cell lymphoma / leukemia or acute biphenotypic leukemia) # 3. Non-Hodgkin's lymphoma following subtypes ( WHO classification ) : Burkitt 's lymphoma (incl. Atypical Burkitt 's lymphoma, Burkitt-like lymphoma ) , diffuse large B-cell lymphoma ( DLBCL particular primary mediastinal , DLBCL with Burkitt -Signature , C-myc-positive DLBCL ), B-cell lymphoblastic lymphoma, T-cell lymphoblastic lymphoma, Large Cell Anaplastic lymphoma, NHL Other
Exclusion criteria
Exclusion criteria: non
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| # Collection of input features and prognostic factors ( including newer methods, such as MRD determination at different times ) # Survey of disease status and selected therapies # Survey of therapy procedure included the overall and disease-free survival, response rate and duration of the various therapies and patient subgroups | — |
Secondary
| Measure | Time frame |
|---|---|
| # Collect data on treatment with newer forms of therapy ( eg molecular therapies ) and use of modern supportive medications ( eg PEG - G - CSF , palifermin ) # Collection of therapy and late effects # Survey of quality of diagnosis and treatment of ALL | — |
Countries
Germany
Contacts
Public ContactNicola Gökbuget
Universitätsklinikum Frankfurt/Main
Outcome results
None listed